- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03129126
The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
December 8, 2023 updated by: Lipella Pharmaceuticals, Inc.
A Multicenter, Dose-Ranging Trial Evaluating the Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
The purpose of this study is to assess the safety and tolerability of three doses of LP-10 (intravesical tacrolimus).
Twelve subjects meeting the inclusion and exclusion criteria will be enrolled and treated in a prospective and multi-center trial with LP-10.
The proposed trial will recruit 12 subjects in a dose-escalation trial where 4 subjects will be allocated into each one of three groups.
Study Overview
Detailed Description
This is a multi-center, dose-ranging study including male and female subjects with refractory moderate to severe hemorrhagic cystitis as determined by a physician.
A total of up to 12 subjects are anticipated and will be enrolled in study sites in the United States.
Enrollment is expected to be completed within one year of initiating the study.
The proposed trial will recruit 12 subjects in a dose-escalation trial where 4 subjects will be allocated into each one of three groups.
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Janet Okonski, BS
- Phone Number: 412-894-1853
- Email: janet.okonski@lipella.com
Study Contact Backup
- Name: Michele Gruber, BS
- Phone Number: 412-894-1853
- Email: michele.gruber@lipella.com
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- University of Arizona
-
-
California
-
San Francisco, California, United States, 94122
- University of California San Francisco
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Michigan
-
Troy, Michigan, United States, 48084
- Michigan Institute of Urology
-
-
New York
-
Poughkeepsie, New York, United States, 12603
- Premier Medical Group
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Temple University
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny Health Network Research Institute
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Males and females, at least 18 years
- History of sterile moderate to severe HC (Grade 2-4) for at least 3 months documented in the medical record with at least 1 episode of macroscopic hematuria with or without clot
- Previous use of medications and/or treatment(s) for HC without success
- Patients of child-bearing capability agree to use a reliable form of birth control (condoms and/or oral contraceptives) during the course of instillation therapy and for 1 week thereafter
- Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the 3 day Hemorrhagic Cystitis Diary (HC Diary) and self-administered questionnaires
Exclusion Criteria:
- History of interstitial cystitis/painful bladder syndrome
- HC due to infection (bacterial, viral or fungal)
- Vesicoureteral reflux disease based on cystogram within past 12 months
- Subject is currently or has previously participated in another therapeutic or device study within 3 months of screening and has not returned to baseline
- Pregnant or lactating
- History of bleeding diathesis or active bleeding peptic ulcer disease
- Life expectancy less than 12 months
- PSA > 10.0 ng/dl (measured within the last 3 months)
- Known allergy to liposomes and/or egg yolk and/or tacrolimus
- Urinary retention requiring daily catheterization
- Previous augmentation cystoplasty
- Subjects currently taking prescribed treatment for HC will be able to continue the treatment throughout the course of the study. If the patient cannot be maintained on a stable dose of the medication(s) throughout the treatment and follow-up period they will be excluded
- Subject with history of intravesical treatment(s) within 1 week prior to Study Visit 1
- Sacral and/or pudendal nerve neuromodulation device (Interstim) within the last 6 months. Subjects would not be excluded if they had Interstim greater than 6 months ago and is on a stable setting.
- Evidence of renal impairment (creatinine > two times the upper limit of normal at Visit 1), hepatic impairment (AST or ALT > three times the upper limit of normal at Visit 1), clinically significant cardiovascular, respiratory, or psychiatric diseases per investigator's judgment
- Post-void residual (PVR) urine volume of > 150 mL at screening
- The presence of any clinically significant systemic disease or condition that in the opinion of the investigator would make the patient unsuitable for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LP-10 2mg
LP-10 (intravesical tacrolimus), 2mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
|
Intravesical tacrolimus
|
Experimental: LP-10 4mg
LP-10 (intravesical tacrolimus), 4mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
|
Intravesical tacrolimus
|
Experimental: LP-10 8mg
LP-10 (intravesical tacrolimus), 8mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
|
Intravesical tacrolimus
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Reported Mean episodes of visible blood
Time Frame: At every patient visit, up to 2 weeks following initial treatment
|
Pre-post changes in mean episodes of visible blood in urine (or blood clots) on 3-day bladder diaries at baseline and primary endpoint
|
At every patient visit, up to 2 weeks following initial treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urine Dipstick Mean episodes of Visible Blood
Time Frame: At every patient visit, up to 2 weeks following initial treatment
|
Mean episodes of visible blood in urine (or blood clots) and urine dipstick for quantitative grading of microscopic hematuria on bladder diaries
|
At every patient visit, up to 2 weeks following initial treatment
|
Mean urine hemoglobin concentration
Time Frame: At every patient visit, up to 2 weeks following initial treatment
|
Mean urine hemoglobin concentration
|
At every patient visit, up to 2 weeks following initial treatment
|
Urine analysis with microscopy
Time Frame: At every patient visit, up to 2 weeks following initial treatment
|
Urine analysis with microscopy including red blood cells per high power field test
|
At every patient visit, up to 2 weeks following initial treatment
|
Whole blood Add to dictionary levels
Time Frame: At every patient visit, up to 2 weeks following initial treatment
|
Whole blood tacrolimus levels
|
At every patient visit, up to 2 weeks following initial treatment
|
Blood chemistry and liver function test
Time Frame: At every patient visit, up to 2 weeks following initial treatment
|
Blood chemistry and liver function test
|
At every patient visit, up to 2 weeks following initial treatment
|
Patient Reported Global Response Assessment Survey Score
Time Frame: At every patient visit, up to 2 weeks following initial treatment
|
Changes in Global Response Assessment (GRA)
|
At every patient visit, up to 2 weeks following initial treatment
|
Patient Reported Urinary frequency
Time Frame: At every patient visit, up to 2 weeks following initial treatment
|
Changes in urinary frequency and incontinence measured on diaries
|
At every patient visit, up to 2 weeks following initial treatment
|
Bladder Cystoscopy
Time Frame: At initial treatment and on final patient visit, up to 2 weeks following initial treatment
|
Cystoscopic changes in bladder
|
At initial treatment and on final patient visit, up to 2 weeks following initial treatment
|
Patient Reported Health Related Quality of Life Survey Score
Time Frame: At every patient visit, up to 2 weeks following initial treatment
|
Changes in Health Related Quality of Life (HRQOL) scores
|
At every patient visit, up to 2 weeks following initial treatment
|
Post void residual urine volume
Time Frame: At every patient visit, up to 2 weeks following initial treatment
|
Post void residual urine volume
|
At every patient visit, up to 2 weeks following initial treatment
|
Patient Reported Pain and Urgency
Time Frame: At every patient visit, up to 2 weeks following initial treatment
|
Change in pain and urgency 10 cm visual analog scales (VAS)
|
At every patient visit, up to 2 weeks following initial treatment
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: At every patient visit, up to 2 weeks following initial treatment
|
Safety data will be collected by ongoing monitoring of adverse events, during the entire duration of the study, including need for blood transfusion, bladder irrigation, emergency room visit, hospitalization, urinary catheterization, and/or surgery in addition to patient reporting of changes in urinary frequency, hematuria/ clots, incontinence, spasm or discomfort.
|
At every patient visit, up to 2 weeks following initial treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2020
Primary Completion (Actual)
August 21, 2023
Study Completion (Actual)
September 29, 2023
Study Registration Dates
First Submitted
April 17, 2017
First Submitted That Met QC Criteria
April 21, 2017
First Posted (Actual)
April 26, 2017
Study Record Updates
Last Update Posted (Estimated)
December 11, 2023
Last Update Submitted That Met QC Criteria
December 8, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Safety and Efficacy of LP-10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemorrhagic Cystitis
-
LIDDE TherapeuticsRecruitingHemorrhagic CystitisFrance
-
Karolinska InstitutetCompletedHemorrhagic CystitisSweden
-
Tata Memorial CentreBhabha Atomic Research Centre (BARC), MumbaiRecruiting
-
Karolinska InstitutetUnknownStem Cell Transplantation | Hemorrhagic Cystitis | Decidual Stromal CellsSweden
-
Assistance Publique - Hôpitaux de ParisRecruitingPelvic Radiation Therapy | Radiation-induced Hemorrhagic CystitisFrance
-
Wuhan Union Hospital, ChinaNot yet recruitingHematopoietic Stem Cell Transplantation | Prevention | Hemorrhagic Cystitis | Moxibustion
-
Wuhan Union Hospital, ChinaNot yet recruitingHematopoietic Stem Cell Transplantation | Treatment | Hemorrhagic Cystitis | Moxibustion
-
AlloVirTerminatedBK Virus Infection | Hemorrhagic CystitisKorea, Republic of, United States, Italy, Sweden, United Kingdom, Spain, France
-
Asan Medical CenterCompletedChronic Interstitial CystitisKorea, Republic of
-
St. Louis UniversityTerminated
Clinical Trials on LP-10
-
Longbio PharmaRecruitingParoxysmal Nocturnal Hemoglobinuria (PNH)China
-
Longbio PharmaActive, not recruitingMyelodysplastic Syndrome (MDS)China
-
Longbio PharmaActive, not recruitingChronic Spontaneous UrticariaChina
-
Longbio PharmaRecruitingSeasonal Allergic RhinitisChina
-
Abbott Medical DevicesTerminatedAtrial Fibrillation | Coronary Arteriosclerosis | Coronary Artery Bypass Graft SurgeryCanada, United Kingdom, Netherlands, Norway, Finland, Germany
-
Centre Hospitalier Universitaire de NiceCompletedHematological MalignanciesFrance
-
Lipella Pharmaceuticals, Inc.William Beaumont HospitalsCompletedInterstitial CystitisUnited States
-
Newave Pharmaceutical IncRecruitingFollicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Hairy Cell Leukemia | CLL/SLLUnited States
-
jingxueRecruitingPancreatic Carcinoma; Lipoprotein a; Overall Survival; PrognosisChina
-
Newave Pharmaceutical IncRecruitingAcute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Small Lymphocytic Lymphoma | Chronic Myelomonocytic Leukemia-2 | Richter Transformation | T-cell-prolymphocytic Leukemia and other conditionsUnited States